search
Back to results

Embolization in Hereditary Coagulopathies (EHCO)

Primary Purpose

Hemophilia, Embolization, Hemarthrosis

Status
Recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
embolization with spherical microparticles embosphere
Sponsored by
University of Sao Paulo General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemophilia

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with hereditary coagulopathies with arthropathy (i.e., chronic synovitis due to hemarthrosis), with X-ray and MRI (documenting synovitis) followed up at the Hemophilia Center HC-FMUSP. Exclusion Criteria: Patients who do not complete the planned assessments Patients who do not accept to continue with the study.

Sites / Locations

  • Instituto de Ortopedia e Traumatologia do Hospital das Clinicas da Faculdade de Medicina da Universidade de São PauloRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Embolization

Arm Description

embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France) of the affected joint, until partial vascular stasis and decharacterization of pathological synovial enhancement.

Outcomes

Primary Outcome Measures

Reduction of synovium thickness by embolization
Measure (in milimeters) changes of synovial thickness in patients with hereditary coagulopathies with arthropathy due to hemarthrosis with MRI (measure synovium thickness)

Secondary Outcome Measures

Reduction of synovitis by embolization
Measure (in milimeters) changes on synovial thickness in patients with hereditary coagulopathies with arthropathy due to hemarthrosis with MRI
Inferior limb strength
Measure changes in muscle strength by timed up and go (by time of performance, in seconds).
Inferior limb strength
Measure changes in muscle strength of lower limbs by 30 seconds sit to stand test (by number of repetitions)
Balance and fall risk
Measure (in seconds, period of time to perform the test) changes in balance and risk of falls by Timed up and go test.
Quality of life of the patient
Measure, according to the scale of the questionnaire, changes in quality of life with Haemophilia - Adult - Quality of life Questionnaires (HAEM-A-QoL, 10 dimensions, 0 to 100, being 0 the best health related quality of life)
Quality of life of the patient
Measure, according to the scale of the questionnaire, changes in quality of life with Knee Injury and Osteoarthritis Outcome Score (KOOS, 0-100, 100 being the best quality of life).
Quality of life of the patient
Measure, according to the scale of the questionnaire, changes in quality of life with by EQ-5D, up to 1, being 1 the best quality of life). Please note: "Since 2009, EQ-5D has been available in three versions: the three-level EQ-5D-3L; the five-level EQ-5D-5L; and a 'youth' adaptation, EQ-5D-Y. Although the EQ is in recognition of the EuroQol group name, the D refers to dimensions, the L signifies level, and the Y stands for youth, the name of the instrument should not be spelled out in this manner as this is inaccurate. Therefore, EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument in general." Brooks R, Boye KS, Slaap B. EQ-5D: a plea for accurate nomenclature. J Patient Rep Outcomes. 2020 Jul 3;4(1):52. doi: 10.1186/s41687-020-00222-9. PMID: 32620995; PMCID: PMC7334333.
Functional capacity
Measure (according to the scale of the questionnaire) changes in functional capacity with Functional Independence Score in Hemophilia (FISH score, 0 to 32, 32 being the best result)
Functional capacity
Measure (according to the scale of the questionnaire) changes in functional capacity with Functional Independence Score by Knee Injury and Osteoarthritis Outcome Score (KOOS, 0-100, 100 being the best result)
Physical capacity
Measure changes in physical capacity by Hemophilia Joint Health Score (HJHS), 0 to 124, 0 being the best result.
Pain of the affected joint
Measure changes in pain by Hemophilia Joint Health Score (HJHS, 0-12, 0 being the best result)
Pain of the affected joint
Measure changes in pain by numerical rating scale (NRS, 0-10, 0 being no pain and 10 being the worst pain possible)
Pain of the affected joint
Measure changes in pain by Knee Injury and Osteoarthritis Outcome Score (KOOS, 0 to 100, 100 being the best result)
Stifness
Measure (0 to 100, 100 being the best result) changes in knee stiffness by Knee Injury and Osteoarthritis Outcome Score (KOOS)

Full Information

First Posted
September 28, 2022
Last Updated
November 16, 2022
Sponsor
University of Sao Paulo General Hospital
Collaborators
Merit Medical Systems, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05629130
Brief Title
Embolization in Hereditary Coagulopathies
Acronym
EHCO
Official Title
Embolization in Hereditary Coagulopathies
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 16, 2023 (Anticipated)
Primary Completion Date
December 31, 2028 (Anticipated)
Study Completion Date
December 31, 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Sao Paulo General Hospital
Collaborators
Merit Medical Systems, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and/or ankles followed up at the Centro de Hemofilia HCFMUSP, after approval by the ethics and research committee. They will undergo imaging tests (X-rays and Magnetic Resonance of knee, elbow, or ankle), physical, pain, quality of life and functional assessments (Hemophilia Joint Health Score, Functional Independence Score in Hemophilia, Perimeter, Test Timed up and Go, 30 second sit and stand test, Haemophilia - Adult - Quality of Life questionnaire (HAEM-A-QoL), Knee Injury and Osteoarthritis Outcome Score, EQ-5D, numerical rating scale for pain and embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France), until partial vascular stasis and decharacterization of pathological synovial enhancement. These evaluations will be performed at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months after the procedure.
Detailed Description
Longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and/or ankles followed up at the Centro de Hemophilia do Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, i.e. HC-FMUSP), after approval by the ethics and research committee and registry at the clinical trials. Patients will be evaluated by imaging (X-rays and Magnetic Resonance of the affected joint, i.e., knee, elbow, and/or ankle); physical and functional assessments (Hemophilia Joint Health Score, Functional Independence Score in Hemophilia, Perimeter of the affected joint(s), Test Timed up and Go, 30 second sit and stand test, Knee Injury and Osteoarthritis Outcome Score (KOOS); quality of life (Haemophilia - adult - quality of life questionnaires (HAEM-A-QoL), Knee Injury and Osteoarthritis Outcome Score (KOOS), EQ-5D; pain measured by numerical rating scale. Volunteers will be submitted to embolization procedure (superselective embolization of target arteries with spherical microparticles embosphere 100-300 micrometers (Biosphere Medical, Roissy, France) of the affected joint(s), until partial vascular stasis and decharacterization of pathological synovial enhancement. These evaluations will be performed at baseline, 1, 3, 6, 12, 24, 36, 48 and 60 months after the procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemophilia, Embolization, Hemarthrosis, Clotting Factor Deficiency, Synovitis, Arthropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
longitudinal, prospective study.
Masking
None (Open Label)
Masking Description
no masking - all treatement
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Embolization
Arm Type
Experimental
Arm Description
embolization procedure (superselective embolization of target arteries with spherical microparticles Embosphere 100-300 micrometers (Biosphere Medical, Roissy, France) of the affected joint, until partial vascular stasis and decharacterization of pathological synovial enhancement.
Intervention Type
Device
Intervention Name(s)
embolization with spherical microparticles embosphere
Intervention Description
embolization of affected joints with spherical microparticles embosphere
Primary Outcome Measure Information:
Title
Reduction of synovium thickness by embolization
Description
Measure (in milimeters) changes of synovial thickness in patients with hereditary coagulopathies with arthropathy due to hemarthrosis with MRI (measure synovium thickness)
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Reduction of synovitis by embolization
Description
Measure (in milimeters) changes on synovial thickness in patients with hereditary coagulopathies with arthropathy due to hemarthrosis with MRI
Time Frame
1, 3 12, 24, 36, 48 and 60 months
Title
Inferior limb strength
Description
Measure changes in muscle strength by timed up and go (by time of performance, in seconds).
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Inferior limb strength
Description
Measure changes in muscle strength of lower limbs by 30 seconds sit to stand test (by number of repetitions)
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Balance and fall risk
Description
Measure (in seconds, period of time to perform the test) changes in balance and risk of falls by Timed up and go test.
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Quality of life of the patient
Description
Measure, according to the scale of the questionnaire, changes in quality of life with Haemophilia - Adult - Quality of life Questionnaires (HAEM-A-QoL, 10 dimensions, 0 to 100, being 0 the best health related quality of life)
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Quality of life of the patient
Description
Measure, according to the scale of the questionnaire, changes in quality of life with Knee Injury and Osteoarthritis Outcome Score (KOOS, 0-100, 100 being the best quality of life).
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Quality of life of the patient
Description
Measure, according to the scale of the questionnaire, changes in quality of life with by EQ-5D, up to 1, being 1 the best quality of life). Please note: "Since 2009, EQ-5D has been available in three versions: the three-level EQ-5D-3L; the five-level EQ-5D-5L; and a 'youth' adaptation, EQ-5D-Y. Although the EQ is in recognition of the EuroQol group name, the D refers to dimensions, the L signifies level, and the Y stands for youth, the name of the instrument should not be spelled out in this manner as this is inaccurate. Therefore, EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument in general." Brooks R, Boye KS, Slaap B. EQ-5D: a plea for accurate nomenclature. J Patient Rep Outcomes. 2020 Jul 3;4(1):52. doi: 10.1186/s41687-020-00222-9. PMID: 32620995; PMCID: PMC7334333.
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Functional capacity
Description
Measure (according to the scale of the questionnaire) changes in functional capacity with Functional Independence Score in Hemophilia (FISH score, 0 to 32, 32 being the best result)
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Functional capacity
Description
Measure (according to the scale of the questionnaire) changes in functional capacity with Functional Independence Score by Knee Injury and Osteoarthritis Outcome Score (KOOS, 0-100, 100 being the best result)
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Physical capacity
Description
Measure changes in physical capacity by Hemophilia Joint Health Score (HJHS), 0 to 124, 0 being the best result.
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Pain of the affected joint
Description
Measure changes in pain by Hemophilia Joint Health Score (HJHS, 0-12, 0 being the best result)
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Pain of the affected joint
Description
Measure changes in pain by numerical rating scale (NRS, 0-10, 0 being no pain and 10 being the worst pain possible)
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Pain of the affected joint
Description
Measure changes in pain by Knee Injury and Osteoarthritis Outcome Score (KOOS, 0 to 100, 100 being the best result)
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months
Title
Stifness
Description
Measure (0 to 100, 100 being the best result) changes in knee stiffness by Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame
1, 3, 6, 12, 24, 36, 48, 60 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with hereditary coagulopathies with arthropathy (i.e., chronic synovitis due to hemarthrosis), with X-ray and MRI (documenting synovitis) followed up at the Hemophilia Center HC-FMUSP. Exclusion Criteria: Patients who do not complete the planned assessments Patients who do not accept to continue with the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
marcia u rezende, MD PhD
Phone
+5511 981226282
Email
marcia.uchoa@hc.fm.usp.br
First Name & Middle Initial & Last Name or Official Title & Degree
Fabiane E Farias, PT
Phone
+ 5511 3062-5531
Email
fabiane.elize@hc.fm.usp.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fabiane E FArias, PT
Organizational Affiliation
IOT-HC-FMUSP (Orthopedics Institute - General Hospital- School of Medicine - University of Sao Paulo
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andre M Assis, MD, PhD
Organizational Affiliation
Radiology Insititute, General Hospital, School Medicine, University of São Paulo
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Paula Villaça, MD, PhD
Organizational Affiliation
Hematology department, General Hospital, School of Medicine, University of Sâo Paulo
Official's Role
Study Director
Facility Information:
Facility Name
Instituto de Ortopedia e Traumatologia do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo
City
São Paulo
ZIP/Postal Code
05403-010
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marcia U Rezende, MD, PhD
Phone
551130625531
Email
marcia.uchoa@hc.fm.usp.br
First Name & Middle Initial & Last Name & Degree
Fabiane P Farias, PT
Phone
55112661-2473
Email
fabiane.elize@hc.fm.usp.br
First Name & Middle Initial & Last Name & Degree
Marcia U Rezende, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Embolization in Hereditary Coagulopathies

We'll reach out to this number within 24 hrs